Amgen's quarterly results top expectations despite Enbrel sales decline

Amgen Inc. on Tuesday reported fourth-quarter profits and sales that topped analysts’ expectations even as revenues dropped for one of its top sellers, the rheumatoid-arthritis drug Enbrel. The biotech company reported fourth-quarter net income of $767 million, or$1.42 per share, versus $1.62 billion, or$3.00 per share, in the year-earlier period. Adjusted per-share earnings of $4.71 topped the FactSet consensus of$4.59. Revenues totaled $8.196 billion in the quarter, up from$6.839 billion a year earlie ...